Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 4/20 | 0.36 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2873467 | 0.81 | LOXL2 (0.43) | CYP3A4LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6038986 | 0.80 | LMNA (0.35) | CYP3A4LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12976770 | 0.80 | CYP3A4 (0.35) | CYP3A4LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2877314 | 0.80 | CYP1A2 (0.44) | CYP3A4LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6038993 | 0.79 | LMNA (0.34) | CYP3A4LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9969422 | 0.75 | LMNA (0.58) | CYP3A4LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6039463 | 0.75 | IDO1 (0.36) | CYP3A4LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL4404602 | 0.74 | IDO1 (0.54) | CYP3A4LMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6038975 | 0.71 | ALDH1A1 (0.40) | LMNAALDH1A1MAPK1KMT2ATDP1 | |
| SCHEMBL6039466 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | claimed |
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014737-A1 | Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors | DNPEP, ASPH, APP | CYP3A4 2960/4885LMNA 533/4885CYP1A2 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.